GSE193767
BRD4 inhibitor MZ1 exerts anti-cancer effects in Neuroblastoma
MZ1 is a newly designed pan-BET-targeting PROTAC that binds to target proteins (BET proteins such as BRD2, BRD3, and BRD4) and recruits them to the ubiquitin/protease pathway for selective destruction. However, the role of MZ1 in NB models has yet to be determined. The effect of MZ1 on NB cells was investigated using RNA-seq analysis in this work.  MZ1 is a newly designed pan-BET-targeting PROTAC that binds to target proteins (BET proteins such as BRD2, BRD3, and BRD4) and recruits them to the ubiquitin/protease pathway for selective destruction. However, the role of MZ1 in NB models has yet to be determined. The effect of MZ1 on NB cells was investigated using RNA-seq analysis in this work. Overall design: mRNA profiles of SK-N-BE(2) cells treated with 750nM MZ1 or same volume DMSO for 36 h were generated by RNA sequencing, in double, using Illumina NovaSeq6000.